Melanie Royce

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

Mark Ayers, W. Fraser Symmans, James Stec et al. · Journal of Clinical Oncology · 2004 · 569 citations

Medicine, Cancer Biology, Oncology +17

Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy

Lajos Pusztai, Tito R. Mendoza, James M. Reuben et al. · Cytokine · 2003 · 316 citations

Medicine, Oncology, Pharmacology +14

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab

Stefan Glück, Jeffrey S. Ross, Melanie Royce et al. · Breast Cancer Research and Treatment · 2011 · 237 citations

Medicine, Oncology, Pharmacology +17

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Aman U. Buzdar, Vera J. Suman, Funda Meric‐Bernstam et al. · The Lancet Oncology · 2013 · 173 citations · Full text

Medicine, Oncology, Pharmacology +17

Ratios of involved nodes in early breast cancer

Vincent Vinh‐Hung, Claire F. Verschraegen, Donald I. Promish et al. · Breast Cancer Research · 2004 · 166 citations · Full text

Medicine, Biostatistics, Oncology +14